RXi Pharmaceuticals (Nasdaq: RXII) is a biopharmaceutical company pursuing the development and commercialization of novel treatments for human diseases using a technology called RNA interference (RNAi). RNAi was discovered by our co-founder, Dr. Craig Mello, who was awarded the 2006 Nobel Prize for his groundbreaking work in this area. By harnessing the power of RNAi, we believe that RXi Pharmaceuticals may be able to develop a new class of therapeutic products that could have a number of distinct advantages over today’s drugs.

RNAi is a naturally occurring mechanism for the regulation of gene expression that has the potential to selectively inhibit the activity of any human gene.  As a result, RNAi may potentially treat human diseases by “turning-off” genes and blocking the production of disease causing proteins before they are made.

RXi was founded by world-leading researchers in the field of RNAi, began operations in January of 2007 and started trading on the Nasdaq in March of 2008.  Our research and development efforts are led by an outstanding team with a strong track record of discovering new technologies and moving RNA based drugs into the clinic.